Halozyme ( Halozyme )

Halozyme

Halozyme's picture

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. Our research targets the extracellular matrix, an area outside the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique scientific expertise that allows us to pursue this target-rich environment for the development of future therapies.

Halozyme press release, blog etc

10/04/2018 - 09:31 Halozyme Publication In The Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects Of PEGPH20 On The Tumor Microenvironment
09/19/2018 - 22:14 Halozyme Therapeutics To Participate In Upcoming Investor Conference
09/17/2018 - 10:37 Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin) In Canada
09/09/2018 - 22:41 Halozyme Appoints Bernadette Connaughton To Board Of Directors
09/05/2018 - 19:15 Halozyme Names Benjamin Hickey As Chief Commercial Officer
08/22/2018 - 00:52 Halozyme Therapeutics To Participate In Upcoming Investor Conferences
07/26/2018 - 09:23 Halozyme Therapeutics To Participate In Upcoming Healthcare Conference
07/26/2018 - 09:17 Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE Technology
07/11/2018 - 12:57 FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
06/11/2018 - 17:02 Halozyme President And Chief Executive Officer, Dr. Helen Torley Named EY Entrepreneur Of The Year 2018 San Diego
06/01/2018 - 07:28 Halozyme Identifies Plasma Biomarkers As Potential Predictors Of Survival In Pancreatic Cancer
03/22/2018 - 12:50 Halozyme Announces Nomination Of Directors For Reelection At 2018 Stockholder Meeting
03/14/2018 - 16:42 Halozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual Conference
01/09/2018 - 14:50 Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018
12/27/2017 - 07:06 Halozyme Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference
12/07/2017 - 04:45 Alexion and Halozyme Enter License Agreement for ENHANZE Technology
11/15/2017 - 10:38 Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences
11/10/2017 - 09:33 Halozyme To Present Nonclinical Data At SITC 2017 Supporting Combination Of PEGPH20 With Checkpoint Inhibitors